The Role of testosterone treatment in patients with metabolic disorders

References

• Nieschlag E. Late-onset hypogonadism: a concept comes of age. Andrology. 2020;8(6):1506–1511.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol. 2016;41(2):196–210.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. Maturitas. 2018;112:46–52.
   PubMed Web of Science ®Google Scholar
• Corona G, Torres LO, Maggi M. Testosterone therapy: What we have learned from trials. J Sex Med. 2020;17(3):447–460.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Lapauw B. Role of testosterone in cognition and mobility of aging men. Andrology. 2020;8(6):1567–1579.
   PubMed Web of Science ®Google Scholar
• Corona G, Guaraldi F, Rastrelli G, et al. Testosterone deficiency and risk of cognitive disorders in aging males. World J Mens Health. 2021;39(1):9–18.
   PubMedGoogle Scholar
• Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598–1605.
   PubMed Web of Science ®Google Scholar
• Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6(2):272–285.
   PubMed Web of Science ®Google Scholar
• Swerdloff R, Wang C. Reflections on the T Trials. Andrology. 2020;8(6):1512–1518.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967–981.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15(13):1903–1926.
   PubMed Web of Science ®Google Scholar
• Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–1111.
   PubMed Web of Science ®Google Scholar
• Saad F, Caliber M, Doros G, et al. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23(1):81–92.
   PubMed Web of Science ®Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99–116.
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418(Pt 2):120–133.
   PubMed Web of Science ®Google Scholar
• Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6(12):3274–3288.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome- induced erectile dysfunction: an experimental study in the rabbit. Mol Cell Endocrinol. 2014;384(1–2):143–154.
   PubMed Web of Science ®Google Scholar
• Maneschi E, Morelli A, Filippi S, et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol. 2012;215(3):347–362.
   PubMed Web of Science ®Google Scholar
• Sarchielli E, Comeglio P, Filippi S, et al. Testosterone improve muscle fiber asset and exercise performance in a metabolic syndrome model. J Endocrinol. 2020;245(2):259–279.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212(1):71–84.
   PubMed Web of Science ®Google Scholar
• Morelli A, Comeglio P, Filippi S, et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol. 2012;132(1–2):80–92.
   PubMed Web of Science ®Google Scholar
• Morelli A, Filippi S, Comeglio P, et al. Physical activity counteracts metabolic syndrome-induced hypogonadotropic hypogonadism and erectile dysfunction in the rabbit. Am J Physiol Endocrinol Metab. 2019;316(3):E519–E535.
   PubMed Web of Science ®Google Scholar
• Marchiani S, Vignozzi L, Filippi S, et al. Metabolic syndrome-associated sperm alterations in an experimental rabbit model: relation with metabolic profile, testis and epididymis gene expression and effect of tamoxifen treatment. Mol Cell Endocrinol. 2015;401:12–24.
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2014;382(1):107–119.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morelli A, et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Mens Health. 2020;38(3):256–270.
   PubMedGoogle Scholar
• Higgins JPTSJ, Savovic J, Page MJ, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane database of systematic reviews. Cochrane Methods. 2016.
   Google Scholar
• Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• Van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. Eur J Endocrinol. 2020;182(1):11–21.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li X, Cai Z, et al. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019;16:1–12.
   Google Scholar
• Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528–540.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–283.
   PubMed Web of Science ®Google Scholar
• Giagulli VA, Castellana M, Lisco G, et al. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8(6):1628–1641.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Tarocchi M, et al. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest. 2016;39(4):473–484.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Corona G, Rastrelli G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12(4):956–965.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European male ageing study. J Clin Endocrinol Metab. 2010;95(4):1810.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, As C. Late-onset hypogonadism: metabolic impact. Andrology. 2020;8(6):1519–1529.
   PubMed Web of Science ®Google Scholar
• Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. Diabetologia. 2020;63(11):2359–2371.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Filippi S, Sforza A, et al. Metabolic syndrome in male hypogonadism. Front Horm Res. 2018;49:131–155.
   PubMed Web of Science ®Google Scholar
• Crean AJ, Senior AM. High-fat diets reduce male reproductive success in animal models: a systematic review and meta-analysis. Obes Rev. 2019;20(6):921–933.
   PubMed Web of Science ®Google Scholar
• Lainez NM, Coss D. Obesity, neuroinflammation, and reproductive function. Endocrinology. 2019;160:2719–2736.
   PubMed Web of Science ®Google Scholar
• Sarchielli E, Comeglio P, Filippi S, et al. Neuroprotective effects of testosterone in the hypothalamus of an animal model of metabolic syndrome. Int J Mol Sci. 2021;22(4):1589.
   PubMed Web of Science ®Google Scholar
• Cangiano B, Duminuco P, Vezzoli V, et al. Evidence for a common genetic origin of classic and milder adult-onset forms of isolated hypogonadotropic hypogonadism. J Clin Med. 2019;8(1):126.
   Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829–843.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Metformin in vitro and in vivo increases adenosine signaling in rabbit corpora cavernosa. J Sex Med. 2014;11(7):1694–1708.
   PubMed Web of Science ®Google Scholar
• Derkach KV, Bakhtyukov AA, Romanova IV, et al. The effect of metformin treatment on the basal and gonadotropin-stimulated steroidogenesis in male rats with type 2 diabetes mellitus. Andrologia. 2020;52(11):e13816.
   PubMed Web of Science ®Google Scholar
• Yu Morina I, Kumar Roy V, Shpakov AO. The effect of metformin treatment on the basal and gonadotropin-stimulated steroidogenesis in male rats with type 2 diabetes mellitus. Andrologia. 2020;52(11):e13816.
   PubMed Web of Science ®Google Scholar
• Liu CY, Chang TC, Lin SH, et al. Metformin ameliorates testicular function and spermatogenesis in male mice with high-fat and high- cholesterol diet-induced obesity. Nutrients. 2020;12([7]):1932.
   Web of Science ®Google Scholar
• Lotti F, Marchiani S, Corona G, et al. Metabolic syndrome and reproduction. Int J Mol Sci. 2021;22(4):1988.
   PubMed Web of Science ®Google Scholar
• Morgante G, Tosti C, Orvieto R, et al. Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome. Fertil Steril. 2011;95(6):2150–2152.
   PubMed Web of Science ®Google Scholar
• Pelusi C, Giagulli VA, Baccini M, et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo- controlled study. PLoS One. 2017;12(9):e0183369.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Comeglio P, Corno C, et al. Testosterone treatment is associated with reduced adipose tissue dysfunction and non alcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest. 2020 Aug 8; Epub ahead of print. PMID: 32772323. DOI:https://doi.org/10.1007/s40618-020-01381-8
   Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1–7.
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Calogero AE, Condorelli R, et al. Andrological characterization of the patient with diabetes mellitus. Minerva Endocrinol. 2009;34:1–9.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733.
   PubMedGoogle Scholar
• Aversa A, Bruzziches R, Francomano D, et al. and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest. 2010;33(11):776–783.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–3503.
   PubMed Web of Science ®Google Scholar
• Gopal RA, Bothra N, Acharya SV, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. EndocrPract. 2010;16:570–576.
   Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol [Oxf]. 2010;73(5):602–612.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome [the TIMES2 study]. Diabetes Care. 2011;34(4):828–837.
   PubMed Web of Science ®Google Scholar
• Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(8):2098–2107.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–856.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82–91.
   PubMed Web of Science ®Google Scholar
• Magnussen LV, Glintborg D, Hermann P, et al. Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. Diabetes Obes Metab. 2016;18(10):980–989.
   PubMed Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21(3):158–169.
   PubMed Web of Science ®Google Scholar
• Khripun I, Vorobyev S, Belousov I, et al. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male. 2019;22(4):241–249.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Konaka H, Nohara T, et al. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: a subanalysis of a prospective randomised controlled trial [EARTH study]. Andrologia. 2018 Feb;50(1):e12815.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Konaka H, Kato Y, et al. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus. Int J Impot Res. 2019;31(1):25–30.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000–1011.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Mansani R, et al. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol. 2004;46(2):222–228.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Cellai I, Santi R, et al. Anti-inflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214(1):31–43.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Cellai I, Filippi S, et al. Anti-inflammatory effects of androgens in the human vagina. J Mol Endocrinol. 2020;65(3):109–124.
   PubMed Web of Science ®Google Scholar
• Comeglio P, Sarchielli E, Filippi S, et al. Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model. J Endocrinol Invest. 2021 Feb 13. DOI:https://doi.org/10.1007/s40618-021-01522-7
   Google Scholar
• Corona G, Mannucci E, Forti G, et al. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl. 2009;32(5):431–441.
   PubMedGoogle Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Metformin for prediabetes. Med Lett Drugs Ther. 2016;58:141.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology [EAA] guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European society of endocrinology. Andrology. 2020;8(5):970–987.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
   PubMed Web of Science ®Google Scholar
• Corona GG, Rastrelli G, Maseroli E, et al. Testosterone replacement therapy and cardiovascular risk: a review. World J Mens Health. 2015;33(3):130–142.
   PubMedGoogle Scholar
• Corona G, Sforza A, Maggi M. Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health. 2017;35(2):65–76.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15(6):820–838.
   PubMed Web of Science ®Google Scholar